Alternate clonal dominance in richter transformation presenting as extranodal diffuse large B-cell lymphoma and synchronous classic Hodgkin lymphoma

Am J Clin Pathol. 2014 Aug;142(2):227-32. doi: 10.1309/AJCP4T9RPXYTXQDE.

Abstract

Objectives: Richter transformation (RT) represents the rare occurrence of a secondary aggressive lymphoma in the setting of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Methods: Here we describe the peculiar case of a patient with trisomy 12+ and atypical (CD5+, CD23-) CLL/SLL who developed a two-step RT with complex morphologic and molecular features.

Results: Molecular analysis of a CLL/SLL population detected two different immunoglobulin rearrangement patterns corresponding to a main peak and a minor peak. Transformation took place both as gastric diffuse large B-cell lymphoma and as a synchronous bone marrow classic Hodgkin lymphoma with the same immunoglobulin rearrangement pattern corresponding to the minor peak detected in CLL/SLL at diagnosis. During chemotherapy, progression occurred as axillary nodal involvement by a CD5+ high-grade lymphoma with an immunoglobulin rearrangement pattern corresponding to the main CLL peak.

Conclusions: In this case, the elaborate clinical and molecular picture may be correlated to an alternate dominance of two distinct clonal populations probably influenced by therapeutic and environmental factors.

Keywords: Clonal dominance; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Richter syndrome.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bone Marrow / immunology
  • Bone Marrow / pathology*
  • Cell Transformation, Neoplastic / immunology
  • Cell Transformation, Neoplastic / pathology*
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / pathology*
  • Hodgkin Disease / therapy
  • Humans
  • Immunoglobulins / immunology
  • Immunoglobulins / metabolism
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Male
  • Neoplasms, Multiple Primary / pathology*
  • Neoplasms, Multiple Primary / therapy
  • Treatment Outcome

Substances

  • Immunoglobulins